Adc Therapeutics Sa (ADCT) Stock Price, Quote & News

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemi...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 41 21 653 02 00

Website: www.adctherapeutics.com

Address:

BiopOle, Route de la Corniche 3B, Epalinges, Switzerland

CrackheadApparel Aug. 18 at 4:26 PM

$ADCT I know there are concerns over FDA's substantial concerns. My sense is that there will potentially be a black box warning for patients over 75. It is a good sign that the trial was not stopped. Personally opinion is the company is still a buy, especially given current price. There has been a lot of good news, unfortunately it has been overshadowed. Good luck y'all!

1 · Reply

anachartanalyst Aug. 17 at 2:01 PM

$ADCT https://anachart.com/wp-content/uploads/2026/08/1786975291_soc-img.jpg

0 · Reply

Kosmokrat Aug. 17 at 12:52 PM

$ADCT It will be an uphill battle for $ADCT to get an approval for ZYNLONTA + Rituximab in the 2nd line treatment scenario. But there is still hope, but I guess chances for approval are well below 50%, even for a Restricted Label Approval (Age-Capped + REMS). But even if there will be no FDA approval for this combination, the current valuation of 1.6 x sales seems quite attractive. However, $ADCT needs to become profitable at some point, and thus needs significantly more revenue. With good results of the LOTIS-7 trial, SP will for sure move back up. As Zynlonta is already approved, I am sure $ADCT will find ways to increase sales. They are not out of options yet.

1 · Reply

Bazziggr Aug. 13 at 6:12 PM

$ADCT SXTC

0 · Reply

Rox22 Aug. 13 at 6:09 PM

$ADCT @Spartrap yeah that was the question i wanted to ask and was pumped the analyst did. Except did the whole 2 question thing and when CEO couldn't remember 2nd instead of clarifying let him dribble through it. So instead if clarity we have to interpret. The data is night and day with patients below age 75 it would seem obvious for full approval below that age, not used above 75 and or black label for above 75 in combo with Rix. looks like its a wait and see with lotis 7 data and how FDA labels or denies

0 · Reply

StocktwitsNews Aug. 13 at 4:56 PM

ADCT Q2 2026 Earnings Summary $ADCT https://stocktwits.com/news/earnings/ai summaries/adct-q2-2026-earnings-summary/cZoq0qNRJLi

0 · Reply

Spartrap Aug. 13 at 4:13 PM

$ADCT really annoying that they didn't understand the last question about if +75 yo will be part of the label changes to be discussed. The question was pretty clear yet the answer was completely unrelated. Was that on purpose? Sucks. My understanding is that pre-sBla meeting was assessing the chances of a full approval, and it clearly won't pass. So now they are assessing whether adding some label restrictions (with supporting data) will do the trick. I wish they had answer that fair and square instead of letting us filling the blanks ;-/

1 · Reply

Cheaslea76 Aug. 13 at 3:42 PM

$ADCT in 1.03

0 · Reply

Golferhack12 Aug. 13 at 3:05 PM

$ADCT company debt wooping 480million

0 · Reply

alikp76 Aug. 13 at 2:12 PM

$ADCT I think not all is lost yet) we have to wait until the end of the year

0 · Reply